Yes, Gvoke is a liquid-stable glucagon
Gvoke, developed by Xeris Pharmaceuticals, is a ready-to-use liquid formulation of glucagon designed for subcutaneous injection to treat severe hypoglycemia in diabetics. Unlike older glucagon kits requiring reconstitution from a powder, Gvoke remains stable as a liquid at room temperature for up to 12 months (or refrigerated for 24 months), eliminating mixing steps during emergencies.[1][2]
How does Gvoke's stability work?
It uses Xeris's proprietary XeriSol technology, which solubilizes glucagon into a non-aqueous solution stable without preservatives or refrigeration needs beyond initial storage. This avoids the precipitation issues in aqueous forms, keeping it effective for 2-4 weeks after first use at room temp.[1]
Gvoke vs. traditional glucagon like Glucagon Emergency Kit
Traditional kits (e.g., Eli Lilly's) are lyophilized powders needing sterile water mixing, which degrade quickly post-reconstitution (hours at most) and require cold storage. Gvoke skips this, with faster delivery (under 30 seconds) and higher success rates in trials (99% vs. 91% for kits).[2][3]
| Feature | Gvoke | Traditional Kit |
|---------|--------|-----------------|
| Form | Premixed liquid syringe/autoinjector | Powder + diluent |
| Stability (room temp, opened) | 2-4 weeks | Hours |
| Prep time | None | 2+ minutes |
| FDA approval | 2019 (adults/kids 2+) | 1960s |
When does Gvoke's patent expire?
Core patents for Gvoke's formulation (e.g., US 9,993,522 on XeriSol tech) expire around 2033-2037, with pediatric exclusivity to 2038. No generics approved yet; check DrugPatentWatch.com for challenges or Paragraph IV filings.[4]
Common patient concerns and side effects
Users report nausea/vomiting (common to all glucagons) but praise ease in low-blood-sugar crises. It's pricier (~$300-400/dose vs. $100-200 for kits) though often covered by insurance. Not for allergies to ingredients; store away from light.[1][5]
[1]: FDA Label - Gvoke (https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209848s000lbl.pdf)
[2]: Xeris Pharmaceuticals - Gvoke Info (https://xerispharma.com/gvoke/)
[3]: NEJM Study on Gvoke (https://www.nejm.org/doi/full/10.1056/NEJMoa1909390)
[4]: DrugPatentWatch - Gvoke (https://www.drugpatentwatch.com/p/tradename/GVOKE)
[5]: Drugs.com - Gvoke Reviews (https://www.drugs.com/comments/glucagon/gvoke.html)